Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company, dedicated to addressing unmet medical and societal needs through a broad pharmaceutical value chain across the globe. It is currently present in more than 85 countries worldwide with robust sales, marketing, and distribution infrastructure. Intas' phenomenal success in North America and Europe has helped to establish itself as a formidable global pharmaceutical brand. “Intas' strength is fuelled by early identification of molecules, building robust API processes, and targeting early launch opportunities in key markets through complete backward integration," an Intas’ spokesperson said.
Intas' first API manufacturing facility was established in 2007 with the goal of developing high-quality, cost-effective products as import substitutes through indigenous R&D. Its API manufacturing facilities are spread across four different locations and are accredited by stringent global regulatory authorities such as the US FDA, MHRA, AFSSAPS (France), COFEPRIS (Mexico), and others, reinforcing its global quality standards. Today, Intas’ APIs are considered to be of global standards and are being used to manufacture finished products to supply highly regulated markets. The company's current manufacturing capacity is 35 MT/Annum for Oncology APIs and 70 MT/Annum for General APIs.
Intas' API manufacturing expertise includes a wide range of reactions such as High Pressure Hydrogenation, Grignard reactions, n-BuLi usage, Halogenation, LAH, and more. In addition to pure chemistry-based APIs, Intas has expanded into segments such as fermentation based products, potent molecules, and hormones, which necessitate not only a dedicated plant and machinery but also specialized equipment and skilled manpower. Intas' focus on difficult-to-manufacture complex products, development of non-infringing routes of synthesis (ROS), innovative design processes, new polymorphs, and in-house biosimilars have helped the company gain a dominant position in Europe, the US, and other key markets.
A Beacon of Hope
As a responsible global healthcare ambassador, Intas confidently stood up to the threat of COVID-19 by utilizing its extensive human expertise, global reach, and scientific capabilities. In the critical early stages of the pandemic, Intas donated up to two million tablets of hydroxychloroquine, as well as two million tablets of a matched placebo, to a World Health Organization endorsed study into the prevention of COVID-19 infection. Understanding the importance of physical immunity as a potentially lifesaving primary defense against the COVID-19 virus, Intas has promptly responded by developing Thymoquinone, a patented powerful immunity booster. This innovative product proved to be one of the preferred adjuvants to standard COVID-19 treatment as well as an effective immunity booster.
Today, Intas’ APIs are considered to be of global standards and are being used to manufacture finished products to supply highly regulated markets
As one of the pioneers in mental health therapy, Intas also addressed the public's deteriorating mental health, which was exacerbated by the pandemic's anxiety. It developed the research breakthrough API – Endoxifen Citrate, which is India's First NCE in the CNS Domain and the World's First Direct PKC Inhibitor for the acute treatment of bipolar disorder manic episodes (with or without mixed features). This breakthrough ended a 50 year-long wait for specific therapy in this disease category.
Turning the Tide
Currently, around 50 percent of APIs are still being imported into the Indian pharmaceutical market from China (as per PwC Report 2020). Regulatory and Quality issues with Chinese suppliers, price rise of critical APIs has led to Indian Companies focusing on indigenous manufacturing and backward integration.
However, Intas is driving a paradigm shift with its complex API manufacturing infrastructure, strong R&D expertise, and strategic facility expansions. Intas’ selection by the Government of India for its Production Linked Incentive (PLI) scheme will add further impetus to its API manufacturing ambitions. Intas intends to utilize the funds to boost its manufacturing capabilities and sharpen its focus on indigenous manufacturing of critical products, which it is currently importing. “Swiftly and steadily, Intas is shaping up to become Atma-Nirbhar and a leader in this critical component of the drug supply chain and continue to create a world of good health, happiness, and hope," shared an Intas’ spokesperson.
We use cookies to ensure you get the best experience on our website. Read more...
